To utilise extended platelet parameters in order to individuate Immune Thrombocytopenia (ITP) from hypo-proliferative causes of thrombocytopenia. To develop the clinical potential of the extended platelet parameters as they pertain to distinguishing different causes of thrombocytopenia from one another. To test the hypothesis that mean platelet component (MPC) and mean platelet mass (MPM) might distinguish between thrombocytopenia related to bone marrow dysfunction and immune mediated destruction of platelets.
Patient to be registered at the Haematology-Oncology department Mount Sinai Roosevelt Hospital. Inclusion criteria are as follows: All individuals age 18yrs and above capable of rendering consent Known ITP confirmed by response to IVIG, glucocorticoids, or WinRho and exclusion of all other possible causes of thrombocytopenia Confirmed aplastic anemia \[as assessed through bone marrow trephine biopsy\]. Chemotherapy-induced thrombocytopenia assessed at time of predicted nadir.
Study Type
OBSERVATIONAL
Enrollment
50
Full blood count with extended platelet parameters
Full blood count with extended platelet parameters
Full blood count with extended platelet parameters
Roosevelt Hospital
New York, New York, United States
Increased platelet density
Time frame: 12 months
mean platelet mass
Time frame: 12 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.